FDA approves a once-weekly growth hormone for children with Turner syndrome
Sogroya was approved for children 2.5 and older. In the phase 3 REAL8 trial, weekly dosing matched daily injections and spared families 313 injection days a year.

Read the original
The reporting lives at Healio. Our summary is checked against it, and we link it on every story.
The FDA approved Sogroya as the first once-weekly growth hormone for children with growth failure linked to Turner syndrome, Healio reported. The approval covers children 2.5 and older. It is based on the phase 3 REAL8 trial, in which weekly dosing matched daily injections. That schedule spares families 313 injection days a year.
Once a week is the new dosing. Daily injections are what the weekly shot matched in the trial. 313 days is the difference in injection days over a year. This is an approval based on that comparison, not a claim about every child's growth.
Plainsboro, New JerseyMedical researchPublic healthGood news on November 20
More good news
Other stories in the same neighborhood of kindness.
HeroesA 73-year-old who swam into a rip current receives the Carnegie Medal
Frank LaFerrara was honored Nov. 19 for swimming about 200 feet into a rip current near Ocean City and towing a panicked girl to safety.
Verified · Carnegie Hero Fund Commission
Health & TechDes Moines University and UnityPoint launch a rural health collaborative
Starting in Webster County, the effort targets earlier cancer screening, radon risk reduction, and an online hub of local resources.
Verified · KCRG
CommunityNJ Ring Finder returns a grandmother's heirloom on his 500th find
Detectorist Ed Trapper pulled Tina Tomeo's ring from drained Lake Barnegat and surprised her with it at work.
Verified · News 12 New Jersey